Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-04-25 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
信息披露暂缓与豁免事务管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy and procedural manual regarding the management of information disclosure delays and exemptions for a company, including definitions, conditions, internal management processes, and confidentiality commitments. It does not contain financial data, earnings, audit results, or any form of report publication or announcement. It is a governance-related document outlining rules and responsibilities for compliance with securities laws and stock exchange regulations. Therefore, it fits best under Governance Information (CGR). The document length is 3634 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2023-04-25 Chinese
益方生物2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the deposit and actual use of raised funds for the year 2022 by the company. It details the amount of funds raised, their deposit, usage, management, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes auditor and sponsor institution opinions on the fund usage. The document is a detailed report on the management and use of capital raised through an IPO, not a general annual report or earnings release. It is not a simple announcement but a substantive report with financial figures and compliance details. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-04-25 Chinese
益方生物2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2023. The report explicitly states it is unaudited and includes comprehensive financial metrics and shareholder information. The length of the document (over 11,000 characters) and the presence of substantive financial data confirm it is a full quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-25 Chinese
2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Directors' Report." It details the independent directors' duties, attendance, committee work, and evaluations for the year 2022. The content focuses on governance, board activities, and oversight functions rather than financial results or audit opinions. It is a report by the independent directors on their performance and observations during the year, which fits the category of Board/Management Information (MANG). The document is substantive and not merely an announcement or certification, and it does not contain financial statements or audit opinions that would classify it as an Annual Report (10-K) or Audit Report (AR). Therefore, the best classification is MANG with high confidence.
2023-04-25 Chinese
益方生物2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It is issued by 益方生物科技（上海）股份有限公司 (InventisBio Co., Limited). The text includes detailed financial data such as net losses, R&D expenses, quarterly financial data, and comprehensive management discussion and analysis sections. It also contains audit opinions from PwC, detailed company background, risk factors, and extensive financial tables. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance. Therefore, the document is classified as an Annual Report (10-K). FY 2022
2023-04-25 Chinese
独立董事关于公司第一届董事会2023年第二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding resolutions passed at the company's first board meeting in 2023. It discusses approval of the 2022 profit distribution plan and a special report on the use of raised funds. The document is short (968 characters) and does not contain full financial statements or detailed financial data. It is an opinion on board meeting resolutions rather than the resolutions themselves or a full report. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions on company matters.
2023-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.